AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04331483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity program
Description: Supervised sessions of at least 15 minutes 4 times a Week combined with unsupervised sessions.~The supervised activities include moderate-intensity aerobic activities (exercise bike), muscle strengthening (dumbbells, elastic bands, medicine balls) and playful situations (ball games, cooperative games, body expression games).~Each patient can also do unsupervised sessions, autonomously, on the bike thanks to a smartphone application developed by the Kiplin company, with challenges to be carried out by teams of 2 to 5 people (team including several patients, possibility to include relatives) over periods of 1 to 3 weeks per challenge.
Study NCT00043069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium carbonate
Study NCT00043069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium carbonate
Study NCT00043069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: calcium carbonate
Study NCT00043069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Study NCT00043069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Study NCT00914498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Local, pre-incisional injection of 20 ml 1% xylocaine
Description: Local, pre-incisional injection of 20 ml 1% xylocaine
Study NCT00914498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local, pre-incisional injection of 20 ml 1% xylocaine
Description: Local, pre-incisional injection of 20 ml 1% xylocaine
Study NCT03928379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3305677
Description: Administered SC
Study NCT03928379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT00043069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cholecalciferol
Study NCT00043069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogen Antagonists
Study NCT00043069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen Antagonists
Study NCT00043069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estrogen Antagonists
Study NCT00043069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate sodium
Study NCT00043069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study NCT00043069 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02364596 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SA4Ag vaccine
Description: Subjects receive 1 intramuscular injection (0.5 mL) of the SA4Ag vaccine.
Study NCT02364596 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood for immunogenicity will be collected from all subjects at various timepoints.
Study NCT00663975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCI 1020
Description: capsules (4,000 units of lipase) will be administered with meals and snacks
Study NCT05230719 — intervention group
Intervention type: PROCEDURE
Intervention: Radial Artery Approach
Description: dTRA or conventional TRA for radical artery approach
Study NCT01536587 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Salmeterol
Description: At visit 1 the sympathetic activity will be registered using microneurographic recordings of efferent muscle sympathetic nerve activity (MSNA) in the peroneal nerve and respiration over 2 hours, after 20 minutes of recording, 1 dose of placebo will be administered and after a further recording period of 45 minutes a dose of salmeterol 50 µg will be administered which will be followed by a further period of data registration. At visit 2 following 4 weeks of inhaled treatment with salmeterol the same procedures will be performed but a placebo inhalation will not be performed.
Study NCT04435964 — intervention group
Intervention type: DRUG
Intervention: Immunotherapy
Description: Patients treated as per clinical prescription with immunocheckpoint inhibitors (ICI) irrespective of treatment schedule, either as single agent or in combination with chemotherapy and/or radiotherapy
Study NCT05614440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthetic + tramadol hydrochloride
Description: Using tramadol hydrochloride and articain HCL for inferior alveolar nerve block
Study NCT05614440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Only local anesthetic
Description: Using articain HCL for inferior alveolar nerve block
Study NCT01109511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naloxone
Study NCT01109511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone
Study NCT00068432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Oral celecoxib twice daily on days 1-28. Courses repeat every 4 weeks.
Study NCT00068432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Receive gemcitabine by vein (IV) over 65 minutes on days 1, 8 and 15. Courses repeat every 4 weeks.
Study NCT02867683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibrotactile Feedback
Description: Balance training Vibrotactile feedback applied to the trunk
Study NCT00645177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-869
Description: 0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle
Study NCT00645177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 90 mg/m2 IV infusion over 1 hour, weekly every 3 out of 4 weeks
Study NCT00645177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: 90 mg/m2 IV infusion over 1 hour, weekly every 3 out of 4 weeks
Study NCT00645177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABT-869
Description: 0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle
Study NCT03715777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium botulinum type A (BoNTA)
Description: Powder and solution for solution for injection Specify total dose: 80 U~Route of administration:
Study NCT00771940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ghrelin
Description: Solvent, cont. infusion
Study NCT01556997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XOMA 985
Description: PERa/AMLb capsule taken once daily by mouth for six weeks
Study NCT01556997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine Besylate
Description: AMLb capsule taken once daily by mouth for six weeks
Study NCT01556997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril Erbumine
Description: PERe capsule taken once daily by mouth for six weeks
Study NCT00734461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone and naltrexone
Description: tablets containing 20 mg or 40 mg oxycodone~/ tablets containing 20 mg or 40 mg oxycodone combined w/0.001 mg or 0.0001 mg naltrexone
Study NCT00734461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone and naltrexone
Description: tablets containing 20 mg or 40 mg oxycodone~/ tablets containing 20 mg or 40 mg oxycodone combined w/0.001 mg or 0.0001 mg naltrexone
Study NCT00734461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxycodone and naltrexone
Description: tablets containing 20 mg or 40 mg oxycodone~/ tablets containing 20 mg or 40 mg oxycodone combined w/0.001 mg or 0.0001 mg naltrexone
Study NCT02695862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Study NCT02695862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Study NCT04146857 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normoxia
Description: Nap in hypoxia chamber at 20.9% oxygen (36 m asl)
Study NCT04146857 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoxia 1
Description: Nap in hypoxia chamber at 15.0% oxygen (simulates 2660 m asl)
Study NCT04146857 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypoxia 2
Description: Nap in hypoxia chamber at 12.8% oxygen (simulates 4000 m asl)
Study NCT06331975 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Radiomic signature
Description: Assessment of radiomic signature and tumor genetic profile in patients with Non Small Cell Lung Cancer (NSCLC)
Study NCT03465709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: Study Drug
Study NCT04398329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-034
Description: HTX-034, low dose
Study NCT00893139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-38583 ophthalmic solution 0.05%
Study NCT00893139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-38583 ophthalmic solution 0.10%
Study NCT00893139 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL-38583 vehicle
Description: Inactive ingredients used as a placebo comparator
Study NCT02088398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-1215
Study NCT01482234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TXT Me
Description: text messages, physical activity, self determination theory, extrinsic motivation, intrinsic motivation, pedometers, walking, prompts
Study NCT03696199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-Acting Local Anesthesia
Description: The cocktail consists of:~* 0.5% Ropivicaine, 24.6 mL~* Clonidine 100 mcg/mL, 0.4mL~* Epinephrine 1mg/mL, 0.5mL~* Saline to total volume of 50 mL (24.5mL of saline)~The total amount of solution prepared is 50mL, but typically 30mL is used based on the size of the incision. The total volume administered will be recorded.
Study NCT03696199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regional Anesthesia
Description: 0.5% ropivicaine - 30mL each sciatic and femoral/saphenous nerve, ultrasound guided
Study NCT04398329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-034
Description: HTX-034, high dose
Study NCT04398329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer lock applicator
Description: Applicator for instillation
Study NCT04398329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Bupivacaine HCl, 50 mg
Study NCT03222505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Honda Stride Assist Device ON
Description: Subjects performed assessments of walking and motor performance while wearing the Honda Stride Assist Device.
Study NCT03222505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Device Worn
Description: Subjects performed assessments of walking and motor performance without wearing the Honda Assist Device.
Study NCT04131816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HeartHome
Description: The HeartHome program is an expanded home-based cardiac rehabilitation program that combines nurse home visits with telephone and electronic supports for participants that allows them to engage in cardiac rehabilitation activities at home.
Study NCT02421549 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unpaired remote monitoring transmitter
Study NCT02470689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diacerin cream
Description: Diacerin tablet solubule in ultraphil cream
Study NCT02470689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diacerin cream
Description: Diacerin tablet solubule in ultraphil cream
Study NCT03251092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-808
Description: Active
Study NCT03251092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTI-808
Description: Active
Study NCT03251092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03251092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT03251092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03251092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTI-428
Description: Active
Study NCT03251092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-428
Description: Active
Study NCT03251092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTI-801
Description: Active
Study NCT03251092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-801
Description: Active
Study NCT01439867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet hydrochloride
Description: Cinacalcet was provided as 5 mg capsules that were opened, and the contents were either sprinkled on soft food or suspended into a sucrose syrup to create a liquid suspension for administration. All doses were administered with food or shortly after a meal at the same time daily.
Study NCT01439867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care may have included vitamin D sterols (25 OH vitamin D and/or 1-25 OH vitamin D and its analogs) at the discretion of the investigator.
Study NCT01949636 — intervention group
Intervention type: OTHER
Intervention: Functional Magnetic Resonance Imaging
Study NCT03142854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol (PEG)
Description: participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
Study NCT03142854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol (PEG)
Description: High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen.
Study NCT01511263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias)
Description: Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.
Study NCT01511263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG
Description: Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.~EGCG, 675 mg/day, oral, for one year.
Study NCT02979106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal
Description: Assessment of postprandial responses to a mixed meal containing fructose in carriers of one mutated ALDOB allele.
Study NCT03597984 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Simultaneous Integrated Boost-SIB on macroscopic metastases
Description: Delivery of a boost on macroscopic secondary lesion with Simultaneous Integrated Boost technique according this schedule:~- 5 Gy x 3 fr (Whole Vertebra) + SIB 10 Gy x 3 fr on the macroscopic disease Gross Tumor Volume - (GTV)
Study NCT02294747 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sliding Hip Screw with Trochanteric Stabilization Plate
Study NCT02294747 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sliding Hip Screw without Trochanteric Stabilization Plate
Study NCT00498472 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-discharge NT-ProBNP based treatment
Description: Discharge date, treatment and follow-up based also on the knowledge of NT-ProBNP levels measured at 2-3 days before discharge.~Discharge may be postponed and medical treatment may be changed when NT-ProBNP is >3000 pg/ml. Changes in medical treatment will include the following: increase in the diuretic dose, association of a different diuretic; combination of digoxin therapy; increase in the dose of the renin-angiotensin inhibitor; association of an ARB; association of a nitrate; short course of i.v. diuretic, vasodilator and/or inotropic therapy.
Study NCT02301377 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spiro PD personal spirometer
Study NCT04227145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SexHealth Mobile
Description: It will integrate two existing services in our community: a mobile medical unit (MMU) operated by Swope Health Services, and SexHealth a point-of-care contraception counseling service that our research team developed for Children's Mercy Hospital's emergency department (ED). Using a menu of adaptive services, SexHealth Mobile will bring contraceptive care to women with SUD (including a subset of women with OUD), if they wish to receive it, at targeted recovery sites Swope currently partners with.
Study NCT01156740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penicillin G, Benzathine
Description: IM BPG; 600,000 U > 27kg or 1,200,000 U \<27 kg)
Study NCT01156740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 750 mg/QD
Study NCT01473277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BT-A (Dysport 500U), Triamcinolone acetonide
Description: All patients will be randomize to receive an intra-articular injection of BT-A (Dysport 500U) or triamcinolone acetonide (40 mg). Both drugs will be reconstituted with 2.0 ml of saline. Both drugs will be injected in the glenohumeral joint with a standard posterior approach. The time of the intra-articular injection od BT-A or steroid will be considered the time zero for each patient. The primary and secondary efficacy variables will be evaluated in all patients at 1 week, 2 weeks, 4 weeks, 3 months and 6 months after the treatment.
Study NCT04237389 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation Index Guided endocardial catheter radiofrequency ablation
Description: Ablation Index (AI) guided catheter RF ablation with circumferential ablation around the right and left PVs and 2 additional lines between the lower and upper PVs (endoBox-lesion).
Study NCT04237389 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: minimally invasive thoracoscopic surgical epicardial ablation.
Description: Description: minimally invasive thoracoscopic surgical epicardial ablation using Box-lesion set, which includes isolation of the right and left PVs, roof and posterior wall lines and removal of the LAA.
Study NCT02387151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesenchymal stromal cells
Description: 2 doses of 1-2x10\^6 allogeneic bone marrow derives MSCs IV per/kg body weight at weeks 25 and 26 after transplantation
Study NCT01780454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-507
Description: T-Cell Depleting Agent
Study NCT01780454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: B-Cell Depleting Agent
Study NCT01780454 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Bone Marrow Depletion
Study NCT01780454 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thymic Irradiation
Study NCT04525599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP3772
Description: Intramuscular (IM) injection
Study NCT04525599 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: Intramuscular injection
Study NCT03121820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantinol tablets, 20 mg
Description: Bioequivalence Memantine Hydrochloride (JSC GEROPHARM, Russia) 20 mg film-coated tablets fasting condition
Study NCT03121820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Akatinol Memantine® tablets, 20 mg
Description: Bioequivalence Memantine Hydrochloride (Merz Pharma GmbH \& Co. KGaA, Germany) 20 mg film-coated tablets fasting condition
Study NCT00642525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast swallow radiography, endoscopy
Description: Contrast swallow radiography is performed using water soluble contrast medium Esophagoscopy is performed according to standard safety guidelines
Study NCT01211301 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food-based, Reduced Energy Diet Plan
Description: Control participants will be provided with a 1000-kcal/d meal plan based on regular foods selected and procured by participants. Food lists, sample menus, and portion size references will be provided.
Study NCT01211301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medifast 5 & 1 Plan
Description: Participants randomized to the Medifast group will enroll online in the Medifast 5 \& 1 Plan. This plan consists of 5 portion-controlled, nutritionally-balanced Medifast Meals plus one Lean \& Green Meal each day. Medifast Meals come in individual packets that are mixed with water and microwaved or refrigerated, and are available in a wide variety of foods and flavors. There are >70 Medifast Meal choices, and Medifast Meals may be used interchangeably, so any five Medifast Meals can be chosen for the 5 \& 1 Plan. The Medifast 5 \& 1 Plan provides approximately 800 to 1,000 kcal/d. The Lean \& Green Meal consists of a lean meat plus salad and/or vegetables selected by the participant. Intervention participants will have online access to Medifast dietitians, Medifast trainers, a Medifast message board, and a Medifast chat room, allowing them to interact with others on the Medifast 5 \& 1 Plan.